Mouse models of RSV infection showed that administration of an anti-IL-33-receptor antibody that blocks the IL-33 cascade can reduce both the Th2 and Th17 environment (especially IL-13 and IL-17A) and the eosinophil recruitment induced by IL-33 after infection. This evidence concerns the gene IL17A and infection.